AI
Tuesday, July 02, 2019 3:58:41 PM
Huge volatility expected in Bluebird Bio on Trial Data Release
The options market is expecting huge moves tomorrow in the Bio company BLUE as the update investors on the trial data listed below. Keep strong watch there could be enormous volume in the coming days.
Phase 3 data for LentiGlobin in HGB-212 (transfusion-dependent beta thalassemia), June 14; updated Phase 1/2 data for LentiGlobin in HGB-204 (beta-thalassemia), June 14; updated Phase 3 data for LentiGlobin in HGB-207, June 14.
The options market is expecting huge moves tomorrow in the Bio company BLUE as the update investors on the trial data listed below. Keep strong watch there could be enormous volume in the coming days.
Phase 3 data for LentiGlobin in HGB-212 (transfusion-dependent beta thalassemia), June 14; updated Phase 1/2 data for LentiGlobin in HGB-204 (beta-thalassemia), June 14; updated Phase 3 data for LentiGlobin in HGB-207, June 14.
Official InvestorsHub (IHUB) Profile for TopMarketGainers.com. Since 2009,
we are the #1 Source For #FREE Winning #NASDAQ & #NYSE-Listed Alerts!
IHUB Board: https://investorshub.advfn.com/Chart-Analysis-TopMarketGainerscom-36847/
Join the InvestorsHub Community
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
